Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at...
View full profile.
Learn about our editorial policies.
ABOVE: © LAURIE O'KEEFE
Approved CAR T-cell therapies have led to remarkable regressions in cancers of the blood and bone marrow, so-called liquid cancers. Scientists are now hoping to apply CAR T therapy to treat solid tumors. Both types of cancer present challenges.
Brain tumor
© LAURIE O’KEEFE
Blood cancer
© LAURIE O’KEEFE
| Solid tumors | Liquid cancers | |
| Heterogeneity | Cells of a solid tumor do not all present the same mix of antigens on their surfaces, so a given CAR will likely miss some of the cancer. | Although all cancerous B cells present the CD19 antigen targeted by approved CAR T therapies, normal B cells do as well, which can lead to severe side effects when healthy cells are destroyed. |
| Microenvironment | Solid tumors produce immune-suppressing agents such as the checkpoint molecule PD-L1. | The blood is T cells’ home turf, and engineered CAR T cells readily expand once they are introduced... |
Read the full story.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
